NASDAQ:ADPT Adaptive Biotechnologies (ADPT) Stock Price, News & Analysis $27.98 +1.15 (+4.29%) Closing price 11/6/2026 04:00 PM EasternExtended Trading$27.63 -0.35 (-1.24%) As of 11/6/2026 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Adaptive Biotechnologies Stock (NASDAQ:ADPT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ADPT alerts:Sign Up Key Stats Today's Range$26.54▼$28.2750-Day Range$23.95▼$29.8452-Week Range$12.00▼$30.74Volume3.33 million shsAverage Volume2.08 million shsMarket Capitalization$4.53 billionP/E RatioN/ADividend YieldN/APrice Target$30.06Consensus RatingModerate Buy Company Overview Adaptive Biotechnologies Corporation (NASDAQ: ADPT) is a biotechnology company focused on using the genetics of the adaptive immune system to develop diagnostic and research tools. Based in Seattle, Washington, the company analyzes immune-cell receptors to help identify and measure disease, support drug development and improve understanding of immune responses. Adaptive’s products include clonoSEQ, a clinical assay used to detect and monitor measurable residual disease in certain blood cancers, including multiple myeloma, acute lymphoblastic leukemia and chronic lymphocytic leukemia. The company also offers research services and platforms, including ImmunoSEQ, which enables researchers and biopharmaceutical companies to profile T-cell and B-cell receptors for applications in immunology, oncology, infectious disease and therapeutic development. Adaptive was founded in 2009 by brothers Chad Robins and Harlan Robins. Its services are used by healthcare providers, academic and medical researchers, pharmaceutical and biotechnology companies, and patients through clinical testing programs. Chad Robins serves as the company’s co-founder and chief executive officer.AI Generated. May Contain Errors. Read More Adaptive Biotechnologies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks33rd Percentile Overall ScoreADPT MarketRank™: 1.659406479715 of 5 starsAdaptive Biotechnologies scored higher than 33% of companies evaluated by MarketBeat, and ranked 711th out of 886 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.9 / 5Analyst RatingModerate Buy Consensus RatingAdaptive Biotechnologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside/DownsideThe consensus price target for Adaptive Biotechnologies is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageAdaptive Biotechnologies has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Adaptive Biotechnologies' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Adaptive Biotechnologies are expected to grow in the coming year, from ($0.40) to ($0.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adaptive Biotechnologies is -62.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adaptive Biotechnologies is -62.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdaptive Biotechnologies has a P/B Ratio of 24.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.97% of the float of Adaptive Biotechnologies has been sold short.Short Interest Ratio / Days to CoverAdaptive Biotechnologies has a short interest ratio ("days to cover") of 5.03.Change versus previous monthShort interest in Adaptive Biotechnologies has recently increased by 1.25%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAdaptive Biotechnologies does not currently pay a dividend.Dividend GrowthAdaptive Biotechnologies does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.24 News SentimentAdaptive Biotechnologies has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Adaptive Biotechnologies this week, compared to 6 articles on an average week.Search InterestOnly 5 people have searched for ADPT on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Adaptive Biotechnologies to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Adaptive Biotechnologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $27,121,836.00 in company stock.Percentage Held by Insiders5.70% of the stock of Adaptive Biotechnologies is held by insiders.Percentage Held by Institutions99.17% of the stock of Adaptive Biotechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Adaptive Biotechnologies' insider trading history. Receive ADPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adaptive Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ADPT Stock News HeadlinesFinancial Contrast: Adaptive Biotechnologies (ADPT) and Its Competitors2 hours ago | americanbankingnews.comAdaptive Biotechnologies (ADPT) Reported Mixed Q3 Results, Is The Stock Fully Valued?November 7 at 9:16 PM | uk.finance.yahoo.comI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.November 8 at 1:00 AM | Behind the Markets (Ad)Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Breaks Above 50-Day Moving Average Following Insider SellingNovember 6 at 3:10 AM | americanbankingnews.comAdaptive Biotechnologies (NASDAQ:ADPT) COO Sells $338,014.45 in StockOctober 30, 2026 | insidertrades.comInsider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells $296,787.38 in StockOctober 27, 2026 | insidertrades.comInsider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells $304,272.41 in StockOctober 17, 2026 | insidertrades.comAdaptive Biotechnologies (NASDAQ:ADPT) Stock: Insider Susan Bobulsky Sells 6,444 SharesOctober 9, 2026 | insidertrades.comSee More Headlines ADPT Stock Analysis - Frequently Asked Questions How have ADPT shares performed this year? Adaptive Biotechnologies' stock was trading at $16.24 at the beginning of 2026. Since then, ADPT stock has increased by 72.3% and is now trading at $27.98. How were Adaptive Biotechnologies' earnings last quarter? Adaptive Biotechnologies Corporation (NASDAQ:ADPT) issued its quarterly earnings data on Wednesday, November, 4th. The company reported $0.02 EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.12. Adaptive Biotechnologies's revenue for the quarter was down 10.7% on a year-over-year basis. Read the conference call transcript. When did Adaptive Biotechnologies IPO? Adaptive Biotechnologies (ADPT) raised $278 million in an initial public offering on Thursday, June 27th 2019. The company issued 15,000,000 shares at $18.00-$19.00 per share. Goldman Sachs, J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Guggenheim Securities, William Blair and BTIG were co-managers. Who are Adaptive Biotechnologies' major shareholders? Top institutional shareholders of Adaptive Biotechnologies include Sumitomo Mitsui Trust Group Inc. (0.68%), Aberdeen Group plc (0.49%), Lisanti Capital Growth LLC (0.13%) and Knights of Columbus Asset Advisors LLC (0.06%). Insiders that own company stock include Chad M Robins, Harlan S Robins, Tycho Peterson, Susan Bobulsky, Julie Rubinstein, Kyle Piskel, Sharon Benzeno, Francis Lo, Stacy L Taylor, Peter M Neupert, Michelle Renee Griffin and Robert Hershberg. View institutional ownership trends. How do I buy shares of Adaptive Biotechnologies? Shares of ADPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Adaptive Biotechnologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adaptive Biotechnologies investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), Block (XYZ), Palantir Technologies (PLTR), Micron Technology (MU) and CRISPR Therapeutics (CRSP). Company Calendar Last Earnings11/04/2026Today11/08/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 ADPT's financial health is in the Green zone, according to TradeSmith. ADPT has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:ADPT CIK1478320 Webwww.adaptivebiotech.com Phone(206) 659-0067Fax206-659-0667Employees624Year Founded2009Price Target and Rating Average Price Target for Adaptive Biotechnologies$30.06 High Price Target$35.00 Low Price Target$19.00 Potential Upside/Downside+7.4%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($0.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$59.50 million Net Margins-23.67% Pretax Margin-23.73% Return on Equity-23.95% Return on Assets-8.01% Debt Debt-to-Equity Ratio1.82 Current Ratio3.97 Quick Ratio4.68 Sales & Book Value Annual Sales$298.01 million Price / Sales15.20 Cash FlowN/A Price / Cash FlowN/A Book Value$1.14 per share Price / Book24.54Miscellaneous Outstanding Shares161,877,000Free Float152,650,000Market Cap$4.53 billion OptionableOptionable Beta2.18 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:ADPT) was last updated on 11/6/2026 by MarketBeat.com Staff. From Our PartnersEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredThe IRS loophole Trump fought to preserve for retirees401(k) balances have reached record highs on a rising stock market and strong job growth. But traditional acco...American Hartford Gold | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredBezos… DOOMED?A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredYour first step can stay on paperIncome Blueprint, created by Matt, helps traders find and evaluate options opportunities. In his walkthrough, ...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptive Biotechnologies Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptive Biotechnologies With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
